4gi.tv

AstraZeneca expands its COVID portfolio

AstraZeneca expanded its COVID-19 antibody portfolio on Tuesday with a $157 million licensing deal for experimental therapies developed by newly launched biotech company RQ Bio.

Share this post:

Share on facebook
Share on twitter
Share on pinterest
Share on whatsapp
Related Posts
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
WordPress Cookie Plugin by Real Cookie Banner